School of Public Health, University of Sydney, Sydney NSW 2006, Australia.
J Dent. 2010 Apr;38(4):307-17. doi: 10.1016/j.jdent.2009.12.003. Epub 2009 Dec 16.
Although articaine has been recommended for providing an improved local anaesthetic effect in patients presenting for dental treatments, a relevant meta-analysis has been lacking. Despite articaine's popularity, there is contradictory evidence to support the claims. The aim of this systematic review was to compare the efficacy and safety of articaine with lignocaine in maxillary and mandibular infiltrations and block anaesthesia in patients presenting for routine dental treatments.
The following databases were searched: Cochrane Central, Medline, Embase, and ProQuest Health and Medical Complete. In addition, the metaRegister of the controlled trials database was searched to identify dissertations and ongoing or unpublished trials, and the Australian division of Septodont (the manufacturer of articaine and lignocaine) was contacted. The bibliographies of identified articles were also searched.
Inclusion was limited to: (1) randomized controlled trials in patients requiring non-complex routine dental treatments; (2) interventions comparing 4% articaine (1:100,000 epinephrine) with 2% lignocaine (1:100,000 epinephrine) for maxillary and mandibular infiltrations and block anaesthesia; and (3) with principal outcome measures of anaesthetic success, post-injection adverse events or post-injection pain. Trial quality was evaluated by assessing randomization, allocation concealment, blinding, intention to treat analyses and how losses to follow up were addressed. Treatment effects were combined by meta-analysis using the random effects method.
Articaine is more likely than lignocaine to achieve an anaesthetic success in the posterior first molar area with a relative risk for success at 1.31 (95% CI 1.12-1.54, P=0.0009). There is no difference in post-injection adverse events between articaine and lignocaine with a relative risk of 1.05 (95% CI 0.66-1.65, P=0.85). However, articaine injection results in a higher pain score as measured by Visual Analogue Scale, than lignocaine at the injection site after anaesthetic reversal with a weighted mean difference of 6.49 (95% CI 0.02-12.96, P=0.05) decreasing to 1.10 (95% CI 0.18-2.02, P=0.02) on the third day after injection.
The results of this systematic review provide support for the argument that articaine is more effective than lignocaine in providing anaesthetic success in the first molar region for routine dental procedures. In addition, both drugs appear to have similar adverse effect profiles. The clinical impact of articaine's higher post-injection pain scores than lignocaine is negligible. Hence, articaine is a superior anaesthetic to lignocaine for use in routine dental procedures. Use in children under 4 years of age is not recommended, since no data exists to support such usage.
尽管阿替卡因已被推荐用于为接受牙科治疗的患者提供更好的局部麻醉效果,但缺乏相关的荟萃分析。尽管阿替卡因很受欢迎,但有相互矛盾的证据支持这些说法。本系统评价的目的是比较阿替卡因与利多卡因在上颌和下颌浸润麻醉和阻滞麻醉中用于常规牙科治疗的患者的疗效和安全性。
检索了以下数据库:Cochrane 中心、Medline、Embase 和 ProQuest Health and Medical Complete。此外,还检索了对照试验注册库,以确定论文和正在进行或未发表的试验,并联系了澳大利亚赛妥健公司(阿替卡因和利多卡因的制造商)。还检索了已确定文章的参考文献。
纳入标准为:(1)需要非复杂常规牙科治疗的患者的随机对照试验;(2)比较 4%阿替卡因(1:100000 肾上腺素)与 2%利多卡因(1:100000 肾上腺素)用于上颌和下颌浸润麻醉和阻滞麻醉的干预措施;(3)主要结局测量指标为麻醉成功率、注射后不良反应或注射后疼痛。通过评估随机化、分配隐藏、盲法、意向治疗分析以及如何处理失访情况来评估试验质量。使用随机效应方法对治疗效果进行荟萃分析。
阿替卡因比利多卡因更有可能在后磨牙区域实现麻醉成功,成功率的相对风险为 1.31(95%CI 1.12-1.54,P=0.0009)。注射后不良反应方面,阿替卡因与利多卡因之间无差异,相对风险为 1.05(95%CI 0.66-1.65,P=0.85)。然而,在麻醉逆转后,阿替卡因注射部位的疼痛评分(视觉模拟评分)高于利多卡因,加权均数差为 6.49(95%CI 0.02-12.96,P=0.05),第三天后降至 1.10(95%CI 0.18-2.02,P=0.02)。
本系统评价的结果为阿替卡因在常规牙科手术中提供麻醉成功率方面优于利多卡因提供了支持。此外,这两种药物似乎具有相似的不良反应谱。阿替卡因注射后疼痛评分高于利多卡因的临床影响可以忽略不计。因此,阿替卡因是常规牙科手术中优于利多卡因的麻醉剂。不建议在 4 岁以下儿童中使用,因为没有数据支持这种用法。